Navigation Links
Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers
Date:8/27/2013

WALTHAM, Mass., Aug. 27, 2013 /PRNewswire/ -- Syndax Pharmaceuticals Inc., which is developing epigenetic therapies for treatment-resistant cancers, today announced it has secured a $26.6 million Series B financing. Participating investors included Domain Associates, MPM Capital, Forward Ventures and RusnanoMedInvest (RMI).

Syndax plans to use the proceeds to continue advancement of its late-stage pipeline of epigenetic-based combination therapies for treatment-resistant cancers, including activities in preparation for an NDA-enabling Phase 3 study of entinostat in metastatic breast cancer. The study is currently being developed by the ECOG-ACRIN Cancer Research Group, which would conduct the study under the sponsorship of the Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI).

"Entinostat represents the most advanced clinical program of an epigenetic therapy in solid tumors," said Arlene M. Morris, Syndax's chief executive officer. "We have a unique opportunity to help a patient population where safe and effective treatments capable of extending survival are needed desperately. The Series B financing enables us to continue to advance entinostat toward registration, where we believe the opportunity in breast cancer and lung cancer alone exceeds $2 billion."

In the completed Phase 2 ENCORE 301 study, entinostat was shown to extend both progression-free survival and overall survival when added to exemestane in postmenopausal women with estrogen receptor-positive (ER+) metastatic breast cancer whose cancer had progressed after treatment with a nonsteroidal aromatase inhibitor. In addition, a potential pharmacodynamic biomarker identified in a subset of patients with ER+ tumors was associated with greater progression-free survival.

About Entinostat

Entinost
'/>"/>

SOURCE Syndax Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO
2. Syndax Pharmaceuticals Announces Publication of Clinical Study Demonstrating that Entinostat Targets Resistance Pathways in Breast Cancer
3. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
4. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
5. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
6. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
7. Icahn Issues Statement Regarding Amylin Pharmaceuticals
8. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
11. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... GABLES, Fla. , Nov. 20, 2014   ... to become the first U.S. commercial producer of Molybdenum-99 ... a contract with INVAP to design its ... Fla. Mo-99 is the parent isotope of ... medicine procedures worldwide. In 2012, Congress passed legislation making ...
(Date:11/21/2014)...   Wellcentive , the industry leader in ... announced today being named one of the four ... .  Sponsored by Intel, the world leader in ... recognizes companies developing leading-edge technology and unique approaches ... Wellcentive,s Mason Beard , senior ...
(Date:11/21/2014)... 21, 2014  Lexicon Pharmaceuticals, Inc. (Nasdaq: ... offering of $80,000,000 aggregate principal amount of 5.25% Convertible ... private offering within the United States ... buyers pursuant to Rule 144A under the Securities Act ... also granted the initial purchasers an option to purchase ...
Breaking Medicine Technology:Coqui RadioPharmaceuticals Inks Deal With INVAP 2Wellcentive Named Finalist for 2014 Intel Innovation Award 2Wellcentive Named Finalist for 2014 Intel Innovation Award 3Lexicon Announces Pricing Of Convertible Senior Notes Offering 2Lexicon Announces Pricing Of Convertible Senior Notes Offering 3
... Results Reported at American Association for Dental Research ... Parion Sciences, Inc., a,privately-held, development-stage pharmaceutical company dedicated ... body,s mucosal,defenses, today announced preliminary results from a ... channel blocker, P-552-02, as a topical,therapy for dry ...
... April 7 A biosimilar product for,treating the ... the,white blood cells of patients is safe and ... a reference,product. This is the result of a ... company Kwizda Pharma GmbH and the Indian manufacturer,INTAS ...
Cached Medicine Technology:Parion Sciences Announces Phase I Clinical Results for Novel Dry Mouth Treatment 2Parion Sciences Announces Phase I Clinical Results for Novel Dry Mouth Treatment 3Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market 2Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market 3
(Date:11/22/2014)... Sandbridge Capital, a private equity ... consumer brand sector, acquired a minority stake in ... to help fund BackJoy’s global growth and accelerate ... proprietary apparel and footwear lines. Sandbridge Capital Managing ... Directors. , BackJoy is a high-growth health and ...
(Date:11/22/2014)... Columbus, OH (PRWEB) November 22, 2014 ... trials for AndroGel side-effects lawsuits have been scheduled ... District Court, Northern District of Illinois. U.S. District Judge ... litigation, issued a Case Management Order (CMO) on November ... as deadlines for attorneys to submit documents and other ...
(Date:11/22/2014)... News) -- Those air-blown hand dryers in public restrooms ... a new study suggests. British researchers placed a ... in order to simulate poorly washed hands. They then ... paper towels to dry their hands. The investigators ... germs around both types of dryers than around towel ...
(Date:11/21/2014)... Haven, CT (PRWEB) November 21, 2014 ... added a veteran radio industry sales professional to its ... Disney, brings 30 years of leadership and sales experience ... office and assume the title of Director of Strategy ... and Development, Robert O’Mara. , Heinemann will handle a ...
(Date:11/21/2014)... 2014 (HealthDay News) -- The cost of diabetes care ... recent years, climbing to more than $322 billion annually, ... cost were seen with prediabetes care, which have risen ... percent, the researchers added. In 2012, excess medical ... than $1,000 for every American. That total includes $244 ...
Breaking Medicine News(10 mins):Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 4Health News:Restroom Hand Dryers Spread More Germs Than Paper Towels, Study Finds 2Health News:Radio Industry Veteran Joins CRN International’s Sales Organization in Detroit 2Health News:Cost of Diabetes Care Keeps Climbing, Report Shows 2
... following ace cricketer Sachin Tendulkar's and several other players complaining ... the sports arena//. ,Tennis elbow, or lateral epicondylitis ... where the outer part of the elbow becomes painful and ... or a direct bang. The problem occurs following overuse of ...
... with type-2 diabetes are at high risk of ... events are the main reason for their decreased ... of peroxisome proliferator-activated receptor-? (PPAR-?) could reduce macrovascular ... treat type-2 diabetes. ,A recent study, published ...
... an independent risk factor for cardiovascular disease in both ... fold relative to nondiabetic subjects and that 80 percent ... of an atherosclerotic event//. In these patients ... and so the presence of even borderline-high-risk LDL-C signals ...
... capable of altering the emotional state of humans. Physiological ... in folk medicine and aromatherapy for a long time//. ... mood enhancing properties by aromatherapists. ,Recently a study, ... & Behavior, was undertaken to investigate the impact of ...
... the benefits of oral ZYVOX for the treatment of ... compared data from 80 health care clinics and compared ... The results show that oral tablets of Linezolid (ZYVOX), ... to health clinics compared to vancomycin. ,This ...
... have reconstructed defective windpipes using tissue engineering in ... growing the sections of cartilage tube // and ... they were in the womb. This technique of ... Undifferentiated stem cell from amniotic fluid, which is ...
Cached Medicine News:Health News:Tennis elbow not new among cricketers, say experts 2Health News:Aromatherapy: Ambient odors of orange and lavender reduce anxiety 2Health News:Oral use of ZYVOX (Linezolid) is better to Intravenous Vancomycin use for Skin Infections 2
... is a SmartBeam platform providing high-performance scanning and ... most vital clinical sites - spine and femur ... ,The full-function DPX Bravo densitometer gives you a ... You can place it in almost any room ...
... System consists of the portable AutoPulse Platform, ... rechargeable battery pack with a state-of-the-art recharger. ... adults with weight up to 300 lbs ... inches (76 to 130 cm) and chest ...
... is an integrated system that will perform ... want it. You no longer need to ... arterial inflow with and without reactive hyperemia ... the time for measurements and the frequency ...
... System combines cutting edge technology with proven Hokanson ... package available in the US and Canada. ,The ... to do vascular examinations in the same order ... waveforms and data in a database. Tests are ...
Medicine Products: